CLDX Celldex Corp: מקדם חוב לטווח ארוך להון

Protected by monoclonal antibody patents, Celldex Therapeutics (CLDX) possesses a significant competitive advantage driven by high R&D expenditures. The company is developing treatments for dermatitis and urticaria, expanding its presence in the immunology segment via barzolitinib. This chart illustrates that the asset's market value is fixed at 0.00. The development of targeted therapies for oncology and inflammation is being conducted in collaboration with leading clinics.

This indicator measures the share of long-term liabilities within the equity structure, reflecting the degree of financial autonomy and reliance on external borrowing. For Celldex Therapeutics (CLDX), which invests in the development of monoclonal antibodies against cancer, a low long-term debt-to-equity ratio is critical to sustaining a prolonged R&D cycle prior to the commercialization of its drugs.